Representative before the EPO

Employment test 51 - 200 employees
Company dna d young and co llp
operating since 1891
Headquarter in London and 2 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

We have observed 40 EP applications Garreth Andrew Duncan has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12704898

COMPOSITE MATERIAL

IPC classification:
B01J 20/26, B01J 20/28, B01J 20/10, B01D 69/14, B01D 67/00, B01D 71/44, B01D 71/30, B01D 71/28, B01D 71/26
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP12708215

2-AMINO-NAPHTHYRIDINE DERIVATIVES

IPC classification:
A61K 31/435, C07D 471/04, A61P 35/00
Applicant:
Concert Pharmaceuticals Inc
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12779411

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

IPC classification:
A61K 31/53, A61K 31/505, A01N 43/66, A01N 43/54, C07D 401/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12738263

SUBSTITUTED 6-AZA-ISOINDOLIN-1-ONE DERIVATIVES

IPC classification:
A61K 31/437, C07D 519/00, C07D 471/04, A61P 37/00, A61P 35/00, A61P 29/00, A61P 19/00, A61P 17/00, A61P 11/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP12861665

METHODS AND COMPOSITIONS FOR TREATING PARKINSON'S DISEASE

IPC classification:
A61K 31/495
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP12767744

METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES

IPC classification:
A61K 31/495
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP12748097

TREATMENT OF TYPE 2 DIABETES WITH FTY720

IPC classification:
A61K 31/137, A61P 3/10
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP11758072

SUBSTITUTED AZAINDOLES

IPC classification:
A61P 35/00, A61K 31/435, C07D 471/04
Applicant:
Concert Pharmaceuticals Inc
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12756614

USE OF ORGANIC COMPOUND FOR THE TREATMENT OF NOONAN SYNDROME

IPC classification:
A61K 31/166, A61P 43/00
Applicant:
Novartis AG
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Karen Dorothee Larbig, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12830938

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

IPC classification:
A61K 31/415, A01N 43/56
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13189355

Compositions for treating cancer

IPC classification:
A61K 31/5025, A61P 35/02, A61P 35/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13772420

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

IPC classification:
A01N 43/54
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP12847217

NOVEL COMPOSITION FOR GENE DELIVERY

IPC classification:
A61K 38/17
Agent:
Multiple attorneys, D Young & Co LLP
Status:
PATENT GRANTED
EP14159994

Method for producing peptide

IPC classification:
C08B 37/00, C07K 14/46, C07K 9/00, C07K 7/06, C07K 5/10, C07K 1/113
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP12809882

PHARMACEUTICAL FORMULATIONS

IPC classification:
A61K 9/48, A61K 9/20, A61K 9/14
Applicant:
Array Biopharma, Inc.
Applicant:
Novartis AG
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Sewkian Rudge, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP12771099

METHODS FOR CHRONIC PAIN MANAGEMENT AND TREATMENT USING HCG

IPC classification:
A61K 38/24, A61K 38/16, A61P 25/04
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Agent:
Jochen Kilchert, Meissner Bolte & Partnerschaft mbB
Status:
EXAMINATION IN PROGRESS
EP13733913

METHODS OF REDUCING RISK OF CARDIOVASCULAR DISEASE

IPC classification:
A61K 31/19, A61P 9/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP14175458

Dipeptidyl peptidase inhibitors

IPC classification:
A61K 31/542, A61K 31/53, A61K 31/519, A61K 31/5025, C07D 513/04, C07D 498/04, C07D 487/04, C07D 471/04, A61P 37/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12768941

BICYCLO[6.1.0]NON-4-YNE REAGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES

IPC classification:
G01N 33/68, G01N 33/531, C07F 9/02, C07D 239/22
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11776961

METHOD OF MAKING AZAINDAZOLE DERIVATIVES

IPC classification:
C07D 471/04
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14179491

Bifidobacteria for Treating myocardial infarction

IPC classification:
A61K 35/74, A61K 31/65, A61P 31/12, A61P 29/00, A61P 9/00, A61P 3/10, A61P 3/04
Applicant:
DuPont Nutrition Biosciences ApS
Agent:
DuPont EMEA
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13176816

Fluoride ion battery compositions

IPC classification:
H01M 6/16, H01M 10/0569, H01M 10/0568, H01M 10/0567, H01M 10/05
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12853870

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF COGNITIVE FUNCTION DISORDERS COMPRISING SPINOSYN

IPC classification:
A61K 31/7048, A61K 31/70, A61P 25/28
Applicant:
University-Industry Cooperation Group of Kyung Hee University
Applicant:
Seoul National University Research & Development Business Foundation
Agent:
Multiple attorneys, D Young & Co LLP
Status:
The patent has been granted
EP12716773

N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES

IPC classification:
A61K 31/5383, C07D 498/14, A61P 29/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13768214

PROCESS OF PREPARING SOLIFENACIN OR SALT THEREOF, AND NOVEL INTERMEDIATE USED IN THE PROCESS

IPC classification:
A61K 31/439, C07D 453/02, C07D 401/12, A61P 13/00
Agent:
Multiple attorneys, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13782134

METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES

IPC classification:
A61K 31/165
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13788352

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

IPC classification:
C07D 239/48
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13809531

PHARMACEUTICAL COMPOSITION CONTAINING FIMASARTAN AND HYDROCHLOROTHIAZIDE

IPC classification:
A61K 31/4422, A61K 31/4184, A61K 9/28, A61K 9/20
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
The patent has been granted
EP13737976

AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS

IPC classification:
A61K 31/506, C07D 519/00, C07D 471/04, A61P 37/00, A61P 35/00, A61P 9/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13742568

5HT3 RECEPTOR ANTAGONISTS

IPC classification:
C07D 498/08, C07D 487/14, C07D 471/02, C07D 451/12, C07D 403/04, C07D 401/14, C07D 401/12, C07D 401/04
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13742355

5-HT3 RECEPTOR ANTAGONISTS

IPC classification:
C07D 498/08, C07D 487/14, C07D 471/02, C07D 451/12, C07D 403/04, C07D 401/14, C07D 401/12, C07D 401/04
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
GRANT OF PATENT INTENDED
EP13745254

DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS

IPC classification:
A61K 31/4025, A61K 31/4015, A61P 19/10, A61P 19/08
Applicant:
Cayman Chemical Company, Inc.
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP13745744

DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS

IPC classification:
A61K 31/4025, A61K 31/4015, C07D 403/12, C07D 207/20, A61P 27/06, A61P 27/02, A61P 25/02, A61P 19/10, A61P 17/14
Applicant:
Cayman Chemical Company, Inc.
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP13750488

QUINOXALINE DERIVATIVES AS GPR6 MODULATORS

IPC classification:
A61K 31/498, C07D 487/04, C07D 471/04, C07D 241/44, A61P 25/00
Applicant:
Takeda Pharmaceutical Company Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED
EP13179744

Administration of mTOR inhibitors

IPC classification:
A61P 35/00, A61K 31/436
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION WITHDRAWN
EP13833473

PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF AURANTII NOBILIS PERICARPIUM AND CRATAEGUS AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES

IPC classification:
A61K 36/752, A61K 36/73, A61P 3/04, A61P 3/00
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION IN PROGRESS
EP13832613

PHARMACEUTICAL COMPOSITION FOR TREATING GASTRO-OESOPHAGEAL REFLUX DISEASE

IPC classification:
A61K 31/733, A61K 31/732, A61K 31/715, A61K 31/7032, A61K 31/702, A61K 31/7016, A61K 31/4439, A61K 31/047, A61K 9/48, A61K 9/20, A61K 9/14, A61K 9/08, A61P 1/04
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
EXAMINATION REQUESTED
EP11817285

DETECTION OF LCAT ACTIVITY

IPC classification:
C12Q 1/48
Agent:
Christopher Spencer Winter, MedImmune Limited
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11833524

METHODS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

IPC classification:
A61P 35/00, A61K 31/505
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11810759

GEMCABENE AND DERIVATIVES FOR TREATING PANCREATITIS

IPC classification:
A61P 1/18, A61K 31/194
Agent:
Garreth Andrew Duncan, D Young & Co LLP
Status:
PATENT GRANTED

Please Sign in to use this feature